{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:35:51Z","timestamp":1787016951730,"version":"build-2736575974"},"reference-count":30,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"unspecified","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014848","name":"Arnold Ventures","doi-asserted-by":"publisher","award":["23-09287"],"award-info":[{"award-number":["23-09287"]}],"id":[{"id":"10.13039\/100014848","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["bmjonc"],"accepted":{"date-parts":[[2025,4,22]]},"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the specificity of postmarketing requirement (PMR) statements and associations between PMR statement specificity and PMR study characteristics, timeliness and regulatory decisions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This was a cross-sectional analysis of publicly available Food and Drug Administration (FDA) databases to characterise PMR statements for oncology accelerated approvals (AAs) between January 2011 and July 2023. Characteristics of trials supporting AA and PMR studies were identified from product labels on the Drugs@FDA database and ClinicalTrials.gov. Main outcomes and measures included PMR statement characteristics, PMR study submission timeliness (on-time vs late) and regulatory decision (regular approval vs withdrawal).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We analysed 181 PMR statements for 161 oncology indications. Most PMR statements specified target population (98%), endpoints (81% (44% included clinical endpoints; 37% surrogate endpoints only)), use of randomisation (63%) and comparator (54%). Fewer PMR statements specified a particular trial or protocol (45%), follow-up duration (30%), enrolment targets (26%), multicentre trial (24%), double-blinding (13%) or enrolment diversity (8%). PMR statements for indications granted regular approval were more likely than those for withdrawn indications to specify follow-up duration\n                      <jats:underline>&lt;<\/jats:underline>\n                      1 year (27% vs 0%, p&lt;0.001), allow endpoints other than overall or progression-free survival (27% vs 4%, p=0.01) and mention a specific trial or protocol (71% vs 36%, p=0.003). Compared to those submitted late, on-time PMR studies had fewer sites (110 vs 156, p=0.03), less use of blinding (20% vs 42%, p=0.02), more use of a continuous trial for AA and PMR (37% vs 8%, p=0.003) and more use of primary endpoints other than overall or progression-free survival (37% vs 6%, p&lt;0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PMR statement specificity for oncology AAs varies substantially. Less rigorous PMR statement and study characteristics were associated with timely PMR study submission and transition to regular approval but with important trade-offs. Given that AAs are granted without demonstrated clinical benefit, improving the balance between PMR study timeliness and rigour should be a priority when negotiating PMR statements.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjonc-2024-000659","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T21:58:02Z","timestamp":1747864682000},"page":"e000659","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Specificity of Food and Drug Administration postmarketing requirements and associations with timely submissions and regulatory decisions for oncology accelerated approvals, 2011\u20132023: a cross-sectional analysis"],"prefix":"10.1136","volume":"4","author":[{"given":"Martin","family":"Kurian","sequence":"first","affiliation":[{"name":"Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J","family":"Ferrell","sequence":"additional","affiliation":[{"name":"University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Ulloa Perez","sequence":"additional","affiliation":[{"name":"University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Hubbard","sequence":"additional","affiliation":[{"name":"University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Joffe","sequence":"additional","affiliation":[{"name":"University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronac","family":"Mamtani","sequence":"additional","affiliation":[{"name":"Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA"},{"name":"University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2692-6306","authenticated-orcid":false,"given":"Ravi B","family":"Parikh","sequence":"additional","affiliation":[{"name":"Emory University Winship Cancer Institute, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7813-9879","authenticated-orcid":false,"given":"Holly Fernandez","family":"Lynch","sequence":"additional","affiliation":[{"name":"University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"key":"2025090109144710000_4.1.e000659.1","unstructured":"FDA cancer accelerated approvals. n.d. Available: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/ongoing-cancer-accelerated-approvals"},{"key":"2025090109144710000_4.1.e000659.2","unstructured":"FDA accelerated approval. n.d. Available: https:\/\/www.fda.gov\/patients\/fast-track-breakthrough-therapy-accelerated-approval-priority-review\/accelerated-approval"},{"key":"2025090109144710000_4.1.e000659.3","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jamaoncol.2017.5618","article-title":"A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics: A Review","volume":"4","author":"Beaver","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025090109144710000_4.1.e000659.4","unstructured":"\u201cDangling\u201d accelerated approvals in oncology | new england journal of medicine. Available: https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMp2104846 [Accessed 04 Apr 2024]."},{"key":"2025090109144710000_4.1.e000659.5","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1001\/jamaoncol.2022.7770","article-title":"Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval","volume":"9","author":"Parikh","year":"2023","journal-title":"JAMA Oncol"},{"key":"2025090109144710000_4.1.e000659.6","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2023.0217","article-title":"Timing of Confirmatory Trials for Drugs Granted Accelerated Approval Based on Surrogate Measures From 2012 to 2021","volume":"4","author":"Deshmukh","year":"2023","journal-title":"JAMA Health Forum"},{"key":"2025090109144710000_4.1.e000659.7","unstructured":"Delays in confirmatory trials for drug applications granted fda\u2019s accelerated approval raise concerns. Available: https:\/\/oig.hhs.gov\/oei\/reports\/OEI-01-21-00401.asp [Accessed 04 Apr 2024]."},{"key":"2025090109144710000_4.1.e000659.8","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1001\/jamainternmed.2022.4226","article-title":"Fulfillment of Postmarket Commitments and Requirements for New Drugs Approved by the FDA, 2013-2016","volume":"182","author":"Brown","year":"2022","journal-title":"JAMA Intern Med"},{"key":"2025090109144710000_4.1.e000659.9","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1001\/jamainternmed.2019.0462","article-title":"Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval","volume":"179","author":"Gyawali","year":"2019","journal-title":"JAMA Intern Med"},{"key":"2025090109144710000_4.1.e000659.10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.2396"},{"key":"2025090109144710000_4.1.e000659.11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.9415"},{"key":"2025090109144710000_4.1.e000659.12","unstructured":"Food and drug omnibus reform act of 2022. 2023. Available: https:\/\/www.thefdalawblog.com\/wp-content\/uploads\/2023\/01\/HPM-FDORA-Summary-and-Analysis.pdf"},{"key":"2025090109144710000_4.1.e000659.13","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2023.1313","article-title":"Extending the US Food and Drug Administration\u2019s Postmarket Authorities","volume":"4","author":"Fernandez Lynch","year":"2023","journal-title":"JAMA Health Forum"},{"key":"2025090109144710000_4.1.e000659.14","doi-asserted-by":"publisher","DOI":"10.1111\/1468-0009.12413"},{"key":"2025090109144710000_4.1.e000659.15","unstructured":"Procedures for developing postmarketing requirements and commitments (SOPP 8415). 2024. Available: https:\/\/www.fda.gov\/media\/90591\/download"},{"key":"2025090109144710000_4.1.e000659.16","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1177\/17407745211005044","article-title":"US Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009-2018","volume":"18","author":"Skydel","year":"2021","journal-title":"Clin Trials"},{"key":"2025090109144710000_4.1.e000659.17","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.k2031","article-title":"Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis","volume":"361","author":"Wallach","year":"2018","journal-title":"BMJ"},{"key":"2025090109144710000_4.1.e000659.18","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1056\/NEJMp2208954","article-title":"The On- and Off-Ramps of Oncology Accelerated Approval","volume":"387","author":"Fashoyin-Aje","year":"2022","journal-title":"N Engl J Med"},{"key":"2025090109144710000_4.1.e000659.19","unstructured":"CDER drug and biologic accelerated approvals based on a surrogate endpoint as of December 31, 2023. n.d. Available: https:\/\/www.fda.gov\/media\/151146\/download?attachment"},{"key":"2025090109144710000_4.1.e000659.20","unstructured":"Drugs@FDA: fda-approved drugs. Available: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/ [Accessed 04 Apr 2024]."},{"key":"2025090109144710000_4.1.e000659.21","unstructured":"Postmarket requirements and commitments. Available: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/pmc\/index.cfm [Accessed 04 Apr 2024]."},{"key":"2025090109144710000_4.1.e000659.22","unstructured":"Home | clinicaltrials.gov. Available: https:\/\/clinicaltrials.gov\/ [Accessed 04 Apr 2024]."},{"key":"2025090109144710000_4.1.e000659.23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00535"},{"key":"2025090109144710000_4.1.e000659.24","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1001\/jamaoncol.2016.5296","article-title":"Overall Survival in Cancer Drug Trials as a New Surrogate End Point for Overall Survival in the Real World","volume":"3","author":"Mailankody","year":"2017","journal-title":"JAMA Oncol"},{"key":"2025090109144710000_4.1.e000659.25","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41591-021-01662-6","article-title":"Cancer treatments should benefit patients: a common-sense revolution in oncology","volume":"28","author":"Gyawali","year":"2022","journal-title":"Nat Med"},{"key":"2025090109144710000_4.1.e000659.26","doi-asserted-by":"crossref","first-page":"114240","DOI":"10.1016\/j.ejca.2024.114240","article-title":"The landscape of checkpoint inhibitors in oncology","volume":"209","author":"Haslam","year":"2024","journal-title":"Eur J Cancer"},{"key":"2025090109144710000_4.1.e000659.27","unstructured":"Clinical trial considerations to support accelerated approval of oncology therapeutics. 2023. Available: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/clinical-trial-considerations-support-accelerated-approval-oncology-therapeutics [Accessed 04 Apr 2024]."},{"key":"2025090109144710000_4.1.e000659.28","doi-asserted-by":"publisher","DOI":"10.1177\/1073110517750615"},{"key":"2025090109144710000_4.1.e000659.29","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s12247-024-09851-9","article-title":"Accelerated Approval for Cancer Drugs in the United States and the Clinical Evidence Required for Conversion to Regular Approval","volume":"19","author":"Kato","year":"2024","journal-title":"J Pharm Innov"},{"key":"2025090109144710000_4.1.e000659.30","unstructured":"Office USGA . Drug safety: FDA expedites many applications, but data for postapproval oversight need improvement | U.S. GAO. Available: https:\/\/www.gao.gov\/products\/gao-16-192 [Accessed 11 Jul 2024]."}],"container-title":["BMJ Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjonc-2024-000659","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T16:14:55Z","timestamp":1756743295000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjoncology.bmj.com\/lookup\/doi\/10.1136\/bmjonc-2024-000659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,5,19]]},"published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1136\/bmjonc-2024-000659"],"URL":"https:\/\/doi.org\/10.1136\/bmjonc-2024-000659","relation":{},"ISSN":["2752-7948"],"issn-type":[{"value":"2752-7948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]}}}